Insights

The Limits of Episodic Data Collection

For years, clinical trials and observational studies have depended on fleeting glimpses: a visit to the clinic every few weeks, a memory-based questionnaire, a quick chat at the end of an appointment. However, we understand that chronic conditions, episodic illnesses, and post-viral syndromes don't exist in static moments. Instead, they fluctuate, experience crashes, micro-recoveries, and subtle pattern changes that occur hour by hour. Conventional research approaches are simply not equipped to capture such granular detail.

Digital health platforms and patient-generated data are quickly transforming healthcare delivery and research. Studies consistently show that mobile apps and electronic patient-reported outcomes (ePROs) improve symptom detection, simplify treatment management, and can even decrease complications and healthcare use across various chronic conditions. Evidence indicates that ePRO systems offer more continuous and structured monitoring compared to traditional clinic visits, resulting in better detection of symptom changes and enhanced patient quality of life (ePRO Systematic Review, 2024).

In oncology, utilising app-based symptom tracking has demonstrated its ability to detect treatment-related side effects earlier and more accurately than traditional retrospective clinician reports during standard visits (Oncology ePRO Study, 2021). These digital systems have revealed notable discrepancies between patient-reported experiences and clinical documentation, underscoring the shortcomings of episodic, appointment-centred data collection methods (Digital Symptom Monitoring Review, Nature Digital Medicine, 2025).

From a research standpoint, it is evident that neglecting to systematically record real-time lived experiences results in the loss of vital insights crucial to advancing personalised healthcare, strengthening safety protocols, and bolstering the evidence supporting new clinical pathways.

Regulatory and Institutional Momentum

Regulators and leading funding organisations for research have increasingly recognised the critical importance of continuous, patient-generated data in scientific progress. The U.S. Food and Drug Administration (FDA) has issued targeted guidance on implementing digital health technologies for remote clinical trial data collection, emphasising that devices, wearables, and software applications can improve trial efficiency, expand participant access, and support the creation of new digital endpoints (FDA Digital Health Technologies Guidance, 2023). Meanwhile, the National Institutes of Health (NIH) has significantly increased funding for projects centred on digital health innovations and remote monitoring, signalling a strategic shift towards making continuous, real-world data a core part of modern evidence collection (NIH Digital Health Funding Analysis, 2024).

This change is reflected in how clinical research is conducted. Recent studies on digital health trials related to cardiovascular conditions have shown a notable rise in the use of patient-reported outcomes as both primary and secondary endpoints, integrating participants' lived experiences alongside traditional physiological data (Cardiovascular Digital Trials Review, Nature Digital Medicine, 2025). Overall, these trends indicate a clear shift towards research models that prioritise clinical metrics and the immediate context, variability, and nuances that only patients can provide.

Patient-Controlled Platforms as Research Infrastructure

This is where a patient-controlled platform like MiKare can serve as an asset for research. Specifically designed to stay with the individual rather than the institution, it records symptoms, context, and behaviour throughout daily life; combines wearable device data; and organises episodes and triggers into a seamless timeline rather than isolated entries. For researchers, this offers access to longitudinal, high-resolution data streams that are challenging and costly to obtain through conventional site-based studies alone.

Observe the ongoing shift: smartphones, smartwatches, and various wearables now quietly monitor metrics such as heart rate, sleep patterns, activity levels, arrhythmias, and more, while applications enable users to track mood, pain, breathlessness, cognitive function, and medication intake. The use of wearables has been steadily increasing, and many users are willing to share their data with healthcare providers, though actual data sharing remains relatively low. This gap between willingness and actual sharing offers an opportunity for deliberately designed patient-centred tools to make a meaningful impact. When patients have control over what data they share, with whom, and for what reasons, and when sharing provides clear benefits to their own care, the experience of participating in research shifts from feeling extractive to collaborative.

Equity and Decentralised Trials

Digital platforms are increasingly facilitating the development of more decentralised and hybrid clinical trial designs. The use of apps and wearables for remote data collection enables participation from individuals who are homebound, located in remote areas, disabled, or balancing caregiving duties, thereby including groups that might otherwise be excluded. Reviews of decentralised trials emphasise better engagement, reduced participant burden, and the potential to assemble more diverse and representative cohorts when digital health tools are implemented thoughtfully. This aspect is crucial, as it directly impacts issues of equity and the applicability of findings to broader populations.

The UK has started exploring how data generated by patients using consumer devices can be integrated with electronic health records to tackle important health issues and support population-level research. When combined with a structured, patient-controlled record like MiKare, this creates a powerful, ethically managed pathway for individuals to own and manage their data, complementing the top-down datasets kept by healthcare systems. Essentially, this change shifts the patient's role from a sporadic research participant to a continuous partner providing ongoing, contextualised insights.

Rigour and Responsibility

Certainly, enthusiasm must be combined with rigour. Regulators are rightly emphasising key issues such as validation of digital endpoints, data quality, algorithmic bias, privacy, and security. Effective platforms will require well-structured governance frameworks, transparent data policies, and strong safeguards around consent, access, and secondary use. However, this does not diminish the main opportunity; rather, it emphasises that tools like MiKare should be developed as consumer devices with supplementary research features, also as research-level infrastructure with patient agency central.

A New Position at the Crossroads

For clinicians and researchers, the question has shifted from whether patient-generated data will influence future studies to how quickly they want to engage in that change. For individuals facing complex, under-researched, or poorly understood conditions, the stakes are even more personal. A platform capable of capturing the subtleties of daily life, such as the crash after a school run, a sudden increase in heart rate while climbing stairs, or subtle cognitive dips after specific foods or medications, is not just a self-management tool. It becomes a way to ensure that their experiences inform better science for future patient groups.

That's why tools like MiKare hold a distinctive position at the crossroads of healthcare and research. They enable individuals to feel recognised and understood today, while subtly aiding the development of more personalised, compassionate, and efficient medical solutions for the future.

For organisations venturing into digital trials, academic institutions developing innovative studies, and individuals who want their lived experiences to be more than just a note in a clinical record, the next step is simple: choose platforms that value your data and your story as important sources of insight.

Subscribing to MiKare demonstrates a personal commitment to clarity and strongly supports a research environment that genuinely values patient-generated data.

The MiKare Health app is now available for download on the Apple App Store, with an Android version launching in March 2026.

In a recent article, ABC News examines the range of emotions Australians are experiencing as artificial intelligence (AI) quickly shifts from a novelty to a necessity. This serves as both a reminder of the challenges ahead and a reaffirmation of MiKare Health's fundamental belief: that technology in health must always prioritise the people it serves.

What Australians Are Saying

Insights shared through the ABC feature reflect a broad mix of curiosity and concern:

• Many workers fear their roles are changing or even vanishing as AI handles more complex tasks once considered impossible.
• Students, teachers, and families feel uneasy about the use of AI in therapy, education, and healthcare, where trust and human care are vital.
• And while efficiency is appealing, real questions remain: Who governs AI? Who decides what's ethical? And do those choices truly reflect human values?

Understanding the Significance for Healthcare and Wellness

MiKare witnesses firsthand the pressure on the healthcare system, with rising chronic illnesses, limited resources, and fragmented communication. AI holds great promise: to keep patients engaged, to summarise clinical notes, and to coordinate families and care teams. However, technology only functions effectively if it is designed with people, not for them. Introducing AI without understanding personal perspectives, cultural contexts, and shared values risks repeating past mistakes: injustice, exclusion, and harm.

It's time to translate clinical ideas like autonomy into language that patients can feel and understand, and to ensure they are being listened to, involved, and able to shape their own care journey.

Distinctive Features of MiKare

• We begin with you, not the algorithm. The main question is: How does this enable you, strengthen your voice, and enhance your wellbeing?
• We link innovation to tangible real-world outcomes. Because in health, life, and trust are essential.
• We embed values of inclusion, transparency, and accountability. AI should never replace care; it should enhance it.

A Call to the Health and Care Sectors

The ABC article serves as a timely wake-up call: the public is paying attention. They are asking, "What will this mean for me?"

At MiKare, we believe that every patient and professional deserves clear answers and genuine involvement.

Let's work together to:

• Create AI tools that are accessible and supportive, rather than alienating.
• Ensure that individuals are involved in design, governance, and monitoring.
• Use better data not only for efficiency but also for safer care and fairer outcomes.

Shaping the Future Together

The rise of AI isn't something happening to us; it's something we must shape together. For all those connected to health (patients, clinicians, carers, families), the real question is: What sort of future are we choosing to create?

MiKare chooses a path where your voice takes centre stage. Where better data results in safer care. Where fairness, inclusion, and human-centred design form the foundation of every solution.

Let's shape the future of health — together.

Initially scheduled for publication by December 2024, the report's findings remain unpublished as of August 2025. When pain becomes an everyday burden, swift action is essential.

Beyond the Waiting Game

This pause extends beyond delays caused by locked folders or administrative sluggishness; it reveals a deeper issue rooted in a system that has long ignored women's pain. The inquiry was established to shed light on the persistent gender pain gap: a troubling divide where women experience chronic pain more often but receive prompt or adequate care less frequently.

Accounts from the 12,000 participants in the investigation revealed a recurring pattern of misdiagnoses, prejudice, and emotional neglect. Women whose symptoms were dismissed as 'psychological', enduring prolonged hardships, trusted the system but were ultimately disappointed by it.

Why the Delay Hurts

Each month that passes without action worsens the hardship faced by women suffering silently, obstructing policy initiatives, delaying updates in medical education, and hindering the development of more comprehensive care approaches. As a prominent supporter states:

Enduring pain is neither just nor normal, and each delay reinforces this abnormality, making it even more difficult to break free.

MiKare Health's Perspective

Our belief is that healthcare systems should adapt to the pace of human needs, rather than being limited by bureaucratic schedules. Tools such as open access to health information, symptom monitoring, and seamless communication are more than features; they act as vital support, especially when traditional care pathways encounter obstacles.

We call on Victorian health authorities to prioritise transparency and clear scheduling. Release the results publicly. Take the necessary actions. Ensure that healthcare is not only clinical but also equitable and timely.